The numbers
The BA.3.2 variant of SARS-CoV-2, first identified in South Africa in November 2024, has quickly spread across the globe, being detected in 29 U.S. states and Puerto Rico. As of March 12, 2026, it has been found in nasal swabs from six U.S. travelers, three airplane wastewater samples, and a total of 260 wastewater samples, highlighting its pervasive presence.
Laboratory studies indicate that BA.3.2 carries approximately 70 to 75 mutations in its spike protein, which could significantly impact the effectiveness of current vaccines. The variant has been reported by at least 23 countries, with a prevalence of 0.55% among 5,238 sequences collected between December 1, 2025, and March 12, 2026. This raises concerns about the variant’s ability to evade antibodies, potentially diminishing vaccine protection.
Phylogenetic analyses have revealed the emergence of two sublineages of BA.3.2, namely BA.3.2.1 and BA.3.2.2, which have been cocirculating with various JN.1 descendant lineages. In several European countries, BA.3.2 has shown prevalences of approximately 10%–40%, indicating a significant foothold in the region.
Researchers emphasize the importance of monitoring BA.3.2, stating, “Monitoring the spread of BA.3.2 provides valuable information about the potential for this new SARS-CoV-2 lineage to evade immunity from a previous infection or vaccination.” This underscores the need for continued genomic surveillance to track the evolution of SARS-CoV-2 and its implications for public health.
The public health impact of COVID-19 remains significant, with estimates suggesting 390,000–550,000 hospitalizations and 45,000–64,000 deaths during the 2024–2025 respiratory virus season. The emergence of BA.3.2 adds another layer of complexity to an already strained healthcare system.
Despite the alarming characteristics of BA.3.2, details remain unconfirmed regarding its overall impact on human health outcomes. Additionally, the extent of its geographic spread may be underestimated due to limited genomic detection capabilities in many countries. As noted by researchers, “Because many countries have limited genomic detection and surveillance capacities, these detections likely underrepresent the actual geographic extent of spread.”
As BA.3.2 continues to circulate, public health officials and researchers are urged to enhance surveillance efforts to better understand the variant’s behavior and its potential effects on vaccine efficacy and public health measures. The ongoing evolution of SARS-CoV-2 necessitates vigilance and adaptability in our response to the pandemic.
